Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886

Cancer Research

Volumn 72, Issue 18, 2012, Pages 4807-4817

  Kim, Seong Muk ^a   Woo, Ji Sun ^b   Jeong, Chang Hyun ^b   Ryu, Chung Heon ^a   Lim, Jung Yeon ^a   Jeun, Sin Soo ^b,c  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ADENOVIRUS VECTOR; DEATH RECEPTOR 5; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SCREENING; DRUG SENSITIVITY; GENE; GENE EXPRESSION REGULATION; GLIOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MESENCHYMAL STEM CELL; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL GENE THERAPY; TRAIL GENE; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FLOW CYTOMETRY; GENETIC THERAPY; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, NUDE; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866414174     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0123     Document Type: Article

References (43)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al.European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
2. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005;23:2411-22.
3. Lawler SE, Peruzzi PP, Chiocca EA. Genetic strategies for brain tumor therapy. Cancer Gene Ther 2006;13:225-33.
4. Hamada H, Kobune M, Nakamura K, Kawano Y, Kato K, Honmou O, et al. Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci 2005;96:149-56.
5. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005;65:3307-18.
6. Miletic H, Fischer Y, Litwak S, Giroglou T, Waerzeggers Y, Winkeler A, et al. Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. Mol Ther 2007;15:1373-81.
7. Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M, et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008;68:9614-23.
8. Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, Mohapatra G, et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A 2009;106:4822-7.
9. Uchibori R, Okada T, Ito T, Urabe M, Mizukami H, Kume A, et al. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J Gene Med 2009;11:373-81.
10. Ryu CH, Park SH, Park SA, Kim SM, Lim JY, Jeong CH, et al. Gene therapy of intracranial glioma using interleukin 12-secreting human umbilical cord blood-derived mesenchymal stem cells. Hum Gene Ther 2011;22:733-43.
11. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
12. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63.
13. Roth W, Isenmann S, Naumann U, Kügler S, Bähr M, Dichgans J, et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence neurotoxicity. Biochem Biophys Res Commun 1999;265:479-83.
14. Lee J, Hampl M, Albert P, Fine HA. Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia 2002;4:312-23.
15. Dyer MJ, MacFarlane M, Cohen GM. Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol 2007;25:4505-6.
16. Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A. TRAIL receptor signaling and modulation: are we on the right TRAIL? Cancer Treat Rev 2009;35:280-8.
17. Kim SM, Oh JH, Park SA, Ryu CH, Lim JY, Kim DS, et al. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. Stem Cells 2010;28:2217-28.
18. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001;294:1871-5.
19. Wang D, DuBois RN. Prostaglandins and cancer. Gut 2006;55:115-22.
20. Shureiqi I, Lippman SM. Lypoxygenase modulation to reverse carcinogenesis. Cancer Res 2001;61:6307-12.
21. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
22. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.
23. Dittmann KH, Mayer C, Rodemann HP, Petrides PE, Denzlinger C. MK-886, a leukotriene biosynthesis inhibitor, induces antiproliferative effects and apoptosis in HL-60 cells. Leuk Res 1998;22:49-53.
24. Ghosh J, Myers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci U S A 1998;95:13182-7.
25. Avis I, Hong SH, Martinez A, Moody T, Choi YH, Trepel J, et al. Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J 2001;15:2007-9.
26. Lim JY, Oh JH, Jung JR, Kim SM, Ryu CH, Kim HT, et al. MK886-induced apoptosis depends on the 5-LO expression level in human malignant glioma cells. J Neurooncol 2010;97:339-46.
27. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Nation Cancer Inst 2004;96:1769-80.
28. Gaiser T, Becker MR, Habel A, Reuss DE, Ehemann V, Rami A, et al. TRAIL-mediated apoptosis in malignant glioma cells is augmented by celecoxib through proteasomal degradation of survivin. Neurosci Lett 2008;442:109-13.
29. Valenti MT, Garbin U, Pasini A, Zanatta M, Stranieri C, Manfro S, et al. Role of ox-PAPCs in the differentiation of mesenchymal stem cells (MSCs) and Runx2 and PPARγ2 expression in MSCs-like of osteoporotic patients. PLoS One 2011;6:e20363.
30. Kim SM, Kim DS, Jeong CH, Kim DH, Kim JH, Jeon HB, et al. CXC chemokine receptor 1 enhances the ability of human umbilical cord blood-derived mesenchymal stem cells to migrate toward gliomas. Biochem Biophys Res Commun 2011;407:741-6.
31. Kim CY, Jeong M, Mushiake H, Kim BM, Kim WB, Ko JP, et al. Cancer gene therapy using a novel secretable trimeric TRAIL. Gene Ther 2006;13:330-8.
32. Park SH, Doh J, Park SI, Lim JY, Kim SM, Youn JI, et al. Branched oligomerization of cell-permeable peptides markedly enhances the transduction efficiency of adenovirus into mesenchymal stem cells. Gene Ther 2010;17:1052-61.
33. Liu X, Yue P, Khuri FR, Sun SY. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 2004;64:5078-83.
34. Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizutani Y, et al. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res 2005;65:5662-7.
35. Blum R, Jacob-Hirsch J, Rechavi G, Kloog Y. Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. Mol Cancer Ther 2006;5:2337-47.
36. Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002;20:1063-8.
37. Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, et al. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res 2010;70:3718-29.
38. Bagci-Onder T, Wakimoto H, Anderegg M, Cameron C, Shah K. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res 2011;71:154-63.
39. Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP, et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 2010;28:1527-33.
40. Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, et al. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 2010;16:1256-63.
41. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-5.
42. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997;388:300-4.
43. Hendruschk S, Wiedemuth R, Aigner A, Töpfer K, Cartellieri M, Martin D, et al. RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro Oncol 2011;13:1074-89.